OSE Immunotherapeutics SA

Paris Stock Exchange OSE.PA

OSE Immunotherapeutics SA Net Income Margin for the year ending December 31, 2023: -1,032.91%

OSE Immunotherapeutics SA Net Income Margin is -1,032.91% for the year ending December 31, 2023, a -964.44% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

OSE Immunotherapeutics SA Net Income Margin for the year ending December 31, 2022 was -97.04%, a -51.50% change year over year.
OSE Immunotherapeutics SA Net Income Margin for the year ending December 31, 2021 was -64.05%, a 59.69% change year over year.
OSE Immunotherapeutics SA Net Income Margin for the year ending December 31, 2020 was -158.91%, a -786.49% change year over year.
OSE Immunotherapeutics SA Net Income Margin for the year ending December 31, 2019 was -17.93%, a -179.85% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

Paris Stock Exchange: OSE.PA

OSE Immunotherapeutics SA

CEO	Dr. Nicolas Poirier Ph.D.
IPO Date	March 30, 2015
Location	France
Headquarters	22, boulevard Benoni Goullin
Employees	52
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials Vaccines

Description

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.

Key trends

Past 5 years